Search results
Results from the WOW.Com Content Network
Ridinilazole (previously known as SMT19969) is an investigational small molecule antibiotic being evaluated for oral administration to treat Clostridioides difficile infection (CDI). In vitro, it is bactericidal against C. difficile and suppresses bacterial toxin production; the mechanism of action is thought to involve inhibition of cell ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
Participants received either sulbactam/durlobactam or colistin (a comparator antibiotic) for up to 14 days. [2] Both treatment arms also received an additional antibiotic, imipenem/cilastatin , as background therapy for potential hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia pathogens other than Acinetobacter ...
Cefiderocol may cause serious and life-threatening allergic reactions, severe diarrhea caused by C. difficile and seizures. [9]An increased rate of mortality was observed in people treated with cefiderocol as compared to other antibiotics in a separate clinical trial in critically ill people with multidrug-resistant Gram-negative bacterial infections.
A Cochrane review found that while it is an effective treatment for shigellosis it also produces more significant adverse effects than other antibiotic drugs. [43] Staphylococcus aureus infections: No: No: No: In vitro and in vivo activity against both non-resistant and methicillin-resistant Staphylococcus aureus (MRSA) infections. [44] [45 ...
For premium support please call: 800-290-4726 more ways to reach us
Avibactam is a non-β-lactam β-lactamase inhibitor [2] developed by Actavis (now Teva) jointly with AstraZeneca.A new drug application for avibactam in combination with ceftazidime was approved by the FDA in 2015 for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic-resistant pathogens, including those caused by multidrug ...
(formerly known as TP-434) received FDA approval on August 27, 2018, for treatment of complicated intra-abdominal infections. [54] Sarecycline: 16+ hours (long) (formerly known as WC 3035) received FDA approval on October 1, 2018, for treatment of moderate to severe acne vulgaris. [55] Sarecycline is a narrow-spectrum antibiotic. [56] [57 ...